Hesperetin Alleviated Experimental Colitis via Regulating Ferroptosis and Gut Microbiota.

Nutrients

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhej

Published: July 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Hesperetin (HT) is a type of citrus flavonoid with various pharmacological activities, including anti-tumor, anti-inflammation, antioxidant, and neuroprotective properties. However, the role and mechanism of HT in ulcerative colitis (UC) have been rarely studied. Our study aimed to uncover the beneficial effects of HT and its detailed mechanism in UC. Experimental colitis was induced by 2.5% dextran sodium sulfate (DSS) for seven days. HT ameliorated DSS-induced colitis in mice, showing marked improvement in weight loss, colon length, colonic pathological severity, and the levels of TNFα and IL6 in serum. A combination of informatics, network pharmacology, and molecular docking identified eight key targets and multi-pathways influenced by HT in UC. As a highlight, the experimental validation demonstrated that PTGS2, a marker of ferroptosis, along with other indicators of ferroptosis (such as ACSL4, Gpx4, and lipid peroxidation), were regulated by HT in vivo and in vitro. Additionally, the supplement of HT increased the diversity of gut microbiota, decreased the relative abundance of Proteobacteria and Gammaproteobacteria, and restored beneficial bacteria (Lachnospiraceae_NK4A136_group and Prevotellaceae_UCG-001). In conclusion, HT is an effective nutritional supplement against experimental colitis by suppressing ferroptosis and modulating gut microbiota.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11279615PMC
http://dx.doi.org/10.3390/nu16142343DOI Listing

Publication Analysis

Top Keywords

experimental colitis
12
gut microbiota
12
colitis
5
hesperetin alleviated
4
experimental
4
alleviated experimental
4
colitis regulating
4
ferroptosis
4
regulating ferroptosis
4
ferroptosis gut
4

Similar Publications

This study aims to assess whether endometriosis causally increases the risk of IBD through Mendelian randomisation (MR) analysis and to elucidate potential mechanisms using in vitro experiments. A two-sample Mendelian randomisation (MR) analysis was conducted using genome-wide association study datasets for endometriosis and IBD, including ulcerative colitis and Crohn's disease. Causal inference was assessed using inverse variance weighting, MR-Egger, and weighted median methods, with MR-PRESSO used to detect horizontal pleiotropy.

View Article and Find Full Text PDF

Introduction: The effect of inflammatory bowel disease (IBD) on adverse in-hospital outcomes after radical prostatectomy (RP) for nonmetastatic prostate cancer (PCa) is not well known.

Materials And Methods: Descriptive analyses, propensity score matching and multivariable logistic regression models were used within the National Inpatient Sample (2000-2019) RP patients, after stratification according to Crohn's disease (CD) vs. ulcerative colitis (UC) vs.

View Article and Find Full Text PDF

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by disruption of intestinal barrier function and complex inflammatory manifestations locally and systemically. Although anti-tumor necrosis factor-α (TNF-α) agents such as Infliximab (IFX) are effective in treating IBD, their intestinal tissue concentration has been regarded as determinant of therapeutic efficacy while was restrained by the large molecular weight. Considering the enhanced expression of human neonatal Fc receptor (hFcRn) in UC tissues, we attempted to deliver the therapeutic entity of IFX into UC tissues by developing a novel dual-acting IFX Fab-F8 (IFX-F8) fusion protein for UC treatment.

View Article and Find Full Text PDF

Ulcerative colitis (UC) is a persistent inflammatory condition marked by the destruction of the intestinal mucosal barrier, infiltration of inflammatory cells, and ulceration. M1/M2 macrophage polarization plays an imperative function in the regulation of inflammation through the nuclear factor-kappa B (NFκB) signaling pathway and modulating microRNA-155 (miR-155). Recent studies have highlighted the anti-ulcerogenic and colo-protective properties of sodium-glucose co-transporter-2 (SGLT2) inhibitors.

View Article and Find Full Text PDF

Usnoflast: A Cutting-Edge NLRP3 Inhibitor Attenuates Colonic Inflammation Across Diverse Immunopathology.

Eur J Pharmacol

September 2025

Zydus Research Centre, Zydus Lifesciences Limited, Sharkhej-Bavla NH No. 8A, Village Moraiya, Changodar, Ahmedabad-382 213, Gujarat, India.

NLR (Nod-like receptor) family pyrin domain containing protein 3 (NLRP3) inflammasome activation is key component of innate immune response and is implicated in many autoimmune conditions. Usnoflast is a novel, selective NLRP3-inflammasome inhibitor and is currently in Phase II for various indications including Ulcerative colitis. Here, we report the effect of usnoflast in several experimental models of intestinal inflammation, some of them for the first time for any NLRP3 inhibitor, which involves both innate and adaptive immune mechanisms.

View Article and Find Full Text PDF